High frequency and prognostic value of MYD88 L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment

The aim of this study was to analyze the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) L265P in diffuse large B-cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). We assessed the MYD88 L265P m...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncol Lett
Hlavní autoři: Yu, Sisi, Luo, Huaichao, Pan, Meiling, Palomino, Luis Angel, Song, Xiaoyu, Wu, Ping, Huang, Jian-Ming, Zhang, Zhihui
Médium: Artigo
Jazyk:Inglês
Vydáno: D.A. Spandidos 2018
Témata:
Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5780752/
https://ncbi.nlm.nih.gov/pubmed/29403563
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2017.7472
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky